Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy in those with type 2 diabetes.

The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, in ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...